Drug intelligence / Profile preview

JCXH-110

Development stage: Preclinical
Lead developer: Immorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**JCXH-110** is a preclinical multivalent messenger RNA vaccine being developed by Jiachen Xihai for prevention of influenza and COVID-19. The candidate uses a single-stranded mRNA construct designed to encode fusion proteins incorporating multiple viral antigens and multimerization domains, including influenza hemagglutinin antigens and a SARS-CoV-2 antigen. Expression of these immunogens is intended to induce antigen-specific humoral and cellular immune responses, providing broad protection against influenza virus strains and SARS-CoV-2.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on JCXH-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JCXH-110.

Explore the full profile